Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 16/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30801907 | 1.00 | USP30 (0.42) | USP30PDE4BGRM5CYP3A4BACE1 | |
| SCHEMBL23113592 | 1.00 | USP30 (0.42) | USP30PDE4BGRM5CYP3A4BACE1 | |
| SCHEMBL23113755 | 1.00 | USP30 (0.42) | USP30PDE4BGRM5CYP3A4BACE1 | |
| SCHEMBL23574052 | 1.00 | USP30 (0.42) | USP30PDE4BGRM5CYP3A4BACE1 | |
| SCHEMBL23573999 | 0.88 | USP30 (0.52) | USP30CYP3A4BACE1 | |
| SCHEMBL23574148 | 0.88 | USP30 (0.52) | USP30CYP3A4BACE1 | |
| SCHEMBL23574000 | 0.88 | USP30 (0.52) | USP30CYP3A4BACE1 | |
| SCHEMBL23574087 | 0.83 | USP30 (0.49) | USP30 | |
| SCHEMBL23574090 | 0.83 | USP30 (0.49) | USP30 | |
| SCHEMBL30801935 | 0.83 | USP30 (0.49) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | USP30, UCHL1, ADRM1 | USP30 1/4885PDE4B 3077/4885GRM5 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.